PULSE BIOSCIENCES, INC. 8-K

What Happened
Pulse Biosciences, Inc. filed a Form 8‑K (Item 5.02) on March 27, 2026 disclosing that on March 23, 2026 its Compensation Committee awarded the Company’s Chief Technology Officer, Darrin R. Uecker, 100,000 restricted stock units (RSUs). The award was made for his continued leadership of the Company’s product development efforts for the treatment of atrial fibrillation and vests in full on the third anniversary of the grant date, subject to the grant agreement and the Company’s Amended and Restated 2017 Equity Incentive Plan.

Key Details

• Recipient: Darrin R. Uecker, Chief Technology Officer.
• Grant size: 100,000 restricted stock units representing 100,000 shares of common stock.
• Grant date: March 23, 2026; 8‑K filed March 27, 2026.
• Vesting: 100% vests on the third anniversary of the grant, subject to award terms and the 2017 Equity Incentive Plan.

Why It Matters
This award ties a senior executive’s compensation to the company’s product-development goals for atrial fibrillation, aligning incentives without immediate cash outflow. For investors, the RSUs represent potential future share issuance and will generate share‑based compensation expense and possible dilution when recognized and settled under accounting and plan terms. The filing does not report any departures, salary changes, or other executive-level transactions beyond this equity grant.